• MJHLS Brand Logo

© 2022 MJH Life Sciences™ , NeurologyLive – Clinical Neurology News and Neurology Expert Insights. All rights reserved.

Alzheimer's Association International Conference

Fosgonimeton Fails to Reach End Points, but Shows Mechanistic Potential in Alzheimer Disease

June 23, 2022

After 26 weeks of treatment, those on fosgonimeton alone without acetylcholinesterase inhibitors showed a potentially beneficial change in event-related potential P300 latency, an outcome of working memory processing speed.

Aducanumab’s Implications for Future Clinical Trials: Pierre N. Tariot, MD

September 09, 2021

In addition to his work study pimavanserin in treating dementia-related psychosis, the director of the Banner Alzheimer’s Institute commented on the potential for aducanumab in Alzheimer disease.

Biomarkers, Tech Advances to Improve Alzheimer Disease Prevention: Pierre N. Tariot, MD

September 08, 2021

The director of Banner Alzheimer’s Institute spoke on the importance of biomarkers in Alzheimer disease, as well as the ongoing improvements in digital technologies.

Conducting Alzheimer Disease Trials Remotely: Pierre N. Tariot, MD

September 07, 2021

Following the COVID-19 pandemic, investigators are seeing a shift towards remote trials in an effort to avoid participants having to be in-person at a brick-and-mortar site.

Addressing Neuropsychiatric Symptoms of Alzheimer Disease

September 07, 2021

Jacobo Mintzer, MD, MPA, discussed a wide range of Alzheimer disease related topics, including the use of methylphenidate, reactions to AAIC, and the aducanumab approval.

The State of Alzheimer Disease Trials: Pierre N. Tariot, MD

September 03, 2021

The director of the Banner Alzheimer’s Institute discussed areas of success and those facing challenges for Alzheimer disease clinical trials.

Rachelle S. Doody, MD, PhD, on DIAN-TU Study Analysis, Additional Insights on Gantenerumab and Crenezumab

September 01, 2021

The global head of Neurodegeneration at Roche/Genentech offered her insights on additional analysis of the DIAN-TU trial of gantenerumab and perspectives on biomarker data.

Understanding Biomarker Trends in Alzheimer via Roche’s NeuroToolKit

August 26, 2021

The toolkit’s assays contain several biomarkers, including Aß 1-42, Aß 1-40, α-syn, GFAP, IL-6, neurogranin, NfL, phosphotau181, S100B, sTREM2, total tau, and YKL-40.

Public Misconceptions About Dementia: James E. Galvin, MD, MPH

August 25, 2021

The director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine discussed the real-world level of dementia education and where it needs improvement.

Improving Rural Community Dementia Knowledge, Screening Rates Using Telemedicine: James E. Galvin, MD, MPH

August 24, 2021

The director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine discussed employing the MoCA-T app as a means of cognitive screening in rural and ethnically diverse populations.